Visci Ltd. (Eye-D)

Developer of a sub-conjunctival implant for sustained release of ophthalmic medications to treat glaucoma.

Biotechnology
Active
Tel Aviv, Israel Founded 2011
Website ↗
Last updated 2026-08-21
Total raised
—
Stage
—
Founded
2011
Headcount
—
HQ
Tel Aviv, Israel
Sector
Biotechnology

About

Visci Ltd. (Eye-D) is an Israeli company developing an innovative Eye-D technology for treating glaucoma. This involves a sub-conjunctival implant that releases the prescribed medication “Latanaprost” in a sustained manner, eliminating the need for daily eye drops. The implant, branded as VS-101, is an in-office medical procedure and is currently in its development phase.

Funding history · 1 round · — total

2013-05
Secondary Undisclosed
★ BioLight Life Sciences Ltd.

Q&A

What is Visci Ltd. (Eye-D)'s primary focus?
Visci Ltd. (Eye-D) is an Israeli company developing a sub-conjunctival implant for the sustained release of ophthalmic medications, specifically Latanaprost, to treat glaucoma.
When was Visci Ltd. (Eye-D) founded?
Visci Ltd. (Eye-D) was founded in 2011.
What is the name of Visci Ltd. (Eye-D)'s core product?
Visci Ltd. (Eye-D)'s core product is the VS-101 implant, which is currently in its development phase.
Which company is the parent of Visci Ltd. (Eye-D)?
Visci Ltd. (Eye-D) is a wholly-owned subsidiary of BioLight Life Sciences Ltd.
What type of medical procedure is the VS-101 implant designed for?
The VS-101 implant is designed to be an in-office medical procedure.
What is the primary sector of Visci Ltd. (Eye-D)?
Visci Ltd. (Eye-D)'s primary sector is Biotechnology.
What is the main technology behind Visci Ltd. (Eye-D)'s product?
The main technology behind Visci Ltd. (Eye-D)'s product is a controlled-release drug delivery platform using medical implants.
Where is Visci Ltd. (Eye-D) headquartered?
Visci Ltd. (Eye-D) is headquartered in Tel Aviv, Israel.

Sectors & technology

Primary sector
Biotechnology
Technologies
Target customers
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)